VAXCYTE INC's ticker is PCVX and the CUSIP is 92243G108. A total of 201 filers reported holding VAXCYTE INC in Q3 2023. The put-call ratio across all filers is 0.83 and the average weighting 0.5%.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q3 2023 | $7,726,783 | -35.0% | 151,565 | -36.4% | 0.00% | -33.3% |
Q2 2023 | $11,892,662 | +704.0% | 238,139 | +503.4% | 0.00% | – |
Q1 2023 | $1,479,261 | -86.0% | 39,468 | -82.1% | 0.00% | -100.0% |
Q4 2022 | $10,560,460 | +1122.3% | 220,239 | +510.9% | 0.00% | – |
Q3 2022 | $864,000 | +5.6% | 36,050 | -4.1% | 0.00% | – |
Q2 2022 | $818,000 | +24.7% | 37,596 | +38.3% | 0.00% | – |
Q1 2022 | $656,000 | +90.7% | 27,189 | +87.9% | 0.00% | – |
Q4 2021 | $344,000 | -18.7% | 14,470 | -13.1% | 0.00% | – |
Q3 2021 | $423,000 | +29.0% | 16,658 | +14.4% | 0.00% | – |
Q2 2021 | $328,000 | – | 14,563 | – | 0.00% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
Medicxi Ventures Management (Jersey) Ltd | 1,049,893 | $53,523,545 | 17.09% |
Pivotal bioVenture Partners Investment Advisor LLC | 793,036 | $40,429,128 | 16.12% |
Kynam Capital Management, LP | 1,302,407 | $66,396,709 | 10.86% |
RA Capital Management | 7,891,254 | $402,296,129 | 7.92% |
COMMODORE CAPITAL LP | 1,100,000 | $56,078,000 | 6.56% |
GREAT POINT PARTNERS LLC | 531,211 | $27,081,137 | 4.93% |
ACUTA CAPITAL PARTNERS, LLC | 121,022 | $6,169,702 | 4.14% |
Frazier Life Sciences Management, L.P. | 1,164,405 | $59,361,367 | 3.94% |
Novo Holdings A/S | 845,000 | $43,078,100 | 3.18% |
BRAIDWELL LP | 1,619,553 | $82,564,812 | 2.61% |